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Introduction: The primary objective was to estimate the cost-
effectiveness of maintenance therapy with pemetrexed (Pem) com-
pared with observation, each with best supportive care, in patients
with advanced non-small cell lung cancer (NSCLC) who have
completed, without progression, at least four cycles of first-line
platinum chemotherapy, particularly in those with nonsquamous cell
histology. Secondary comparisons included Pem with erlotinib (Erl)
or Pem with bevacizumab (Bev).
Methods: A semi-Markov model was developed to compare the
3-year impact of Pem with three other alternatives for maintenance
therapy from a United States payer perspective. Data from random-
ized controlled clinical trials provided clinical inputs. Medicare
reimbursement rates were used to determine drug costs. A retro-
spective claims database analysis was used to obtain estimates of
other direct NSCLC-related costs.
Results: In the prespecified subset of patients with nonsquamous
cell histology only, the incremental cost per life-year gained was
$122,371 for Pem to observation and $150,260 for Pem to Erl, and
Bev was dominated by Pem. In all patients with advanced NSCLC
regardless of histologic subtype, using Pem as maintenance therapy
led to an incremental cost per life-year gained of $205,597 compared
with observation and $312,341 compared with Erl.
Conclusions: Compared with observation and other agents used
and/or reimbursed for maintenance therapy in advanced NSCLC,
Pem may be considered cost-effective, particularly in patients with
nonsquamous cell histology. This analysis is the first to evaluate the
cost-effectiveness of maintenance therapy in advanced NSCLC and
emphasizes the importance of histology in identifying the appropri-
ate patient for Pem maintenance therapy.
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Cost-effectiveness.
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In patients with advanced or metastatic (stage IIIB/IV)non-small cell lung cancer (NSCLC), clinical guidelines
recommend the use of two-drug combination regimens (dou-
blets) as first-line therapy.1–3 In patients with stage III dis-
ease, no more than four cycles of chemotherapy is recom-
mended, and a maximum of six cycles is recommended for
stage IV patients.2,4 Historically, treatment for advanced
NSCLC involved waiting until disease progression after the
first-line regimen before administering second-line therapy.5
More recently, maintenance therapy has been used between
first- and second-line chemotherapy in patients with advanced
NSCLC for those patients who achieve at least stable disease
(SD) and are still in generally good condition after first-line
induction therapy.
Maintenance therapy is the prolongation of induction
chemotherapy by administering additional drug(s) at the end
of a defined number of initial chemotherapy cycles after
achieving the maximum tumor response. It is continued either
for a defined period of time or until evidence of disease
progression in the absence of significant toxicity.6 Mainte-
nance therapy can include a drug prescribed in the induction
regimen or a different noncross-resistant agent. Selecting a
well-tolerated agent for maintenance therapy allows treat-
ment to be extended to prolong progression-free survival
(PFS) or overall survival (OS) without increasing toxicity.4
Over the last 5 years, there have been a large number of
trials involving maintenance in patients with advanced
NSCLC including evaluation of cytotoxic (e.g., paclitaxel,
docetaxel, and gemcitabine [Gem]) and noncytotoxic agents
(e.g., erlotinib [Erl] and bevacizumab [Bev]).7–16 The major-
ity of these trials lacked a placebo control arm, and most were
not adequately powered to detect a significant survival benefit
for maintenance therapy.
The first study to demonstrate a significant improve-
ment in disease progression with maintenance therapy eval-
uated induction therapy for cisplatin (Cis) plus Gem for four
cycles followed by Gem maintenance therapy until disease
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progression compared with best supportive care (BSC) alone.
Median time to progression from initiation of Cis/Gem was
significantly longer for Gem compared with BSC (6.6 months
versus 5.0 months, p  0.001). For the maintenance period,
patients receiving Gem also had a significantly better median
time to progression of 3.6 months compared with 2.0 months
with BSC (p  0.001).12 The secondary end point of OS
numerically favored Gem maintenance but was not statisti-
cally significant.
In October 2006, Bev in combination with carboplatin
(Carb) plus paclitaxel (Pac) was approved for use as first-line
therapy in patients with advanced nonsquamous NSCLC in
the United States. Approval was based on one study evaluating
six cycles of the triplet followed by maintenance therapy with
Bev monotherapy every 3 weeks until disease progression,
which showed improvements in PFS and OS compared with
Carb/Pac in patients with nonsquamous NSCLC.13 However, the
specific benefit of maintenance therapy with Bev until disease
progression was not evaluated separately from the induction
treatment regimen. Thus, the true efficacy of Bev maintenance
therapy has yet to be demonstrated.
Already approved for previously treated advanced
NSCLC patients, the efficacy of Erl as maintenance therapy after
first-line treatment with a platinum-based chemotherapy regi-
men has been evaluated in a randomized, controlled, phase 3
clinical trial.17 PFS was significantly prolonged with Erl 150
mg/d compared with placebo (hazard ratio [HR]  0.71, 95%
confidence interval [CI] 0.62–0.82, p 0.0001) in all patients
with advanced NSCLC. Maintenance therapy with Erl demon-
strated significant improvements in PFS compared with placebo
in both patients with squamous cell carcinoma (HR 0.76, p
0.0148, n  359) or nonsquamous cell carcinoma (HR  0.68,
p 0.0001, n 525).18 OS was increased with Erl maintenance
therapy compared with placebo (median 12 months versus 11
months, HR  0.81, p  0.0088).19,20
Pemetrexed (Pem) is an antifolate antineoplastic agent
currently approved in the United States as first-line therapy in
combination with Cis and as single-agent second-line therapy
for the treatment of patients with locally advanced or meta-
static NSCLC with nonsquamous cell histology.21 Single-
agent Pem was recently approved as maintenance therapy for
nonsquamous NSCLC based on a global, phase 3, random-
ized, double-blind, placebo-controlled study of Pem immedi-
ately after platinum-based induction treatment for advanced
NSCLC where it was shown to significantly improve PFS and
OS compared with placebo (Table 1). In all patients with
advanced NSCLC, regardless of histology, median OS was
13.4 months for patients treated with Pem maintenance ther-
apy and 10.6 months for patients who received placebo
(HR  0.79, p  0.012), which represented a 21% reduction
in the risk of death for patients receiving maintenance Pem.
Median PFS was also significantly longer in patients who
received maintenance Pem compared with those who received
placebo (4.3 versus 2.6 months, HR  0.50, p  0.0001).22
Consistent with the results from other phase 3 clinical
trials of Pem in advanced NSCLC,23 this study demonstrated
the greatest benefit in patients with advanced NSCLC with
nonsquamous cell histology. In patients with nonsquamous
NSCLC (i.e., adenocarcinoma, large cell carcinoma, or his-
tology not otherwise specified), Pem maintenance therapy led
to significant improvements in PFS (HR 0.47, p 0.0001).
Median OS was 15.5 months for nonsquamous patients re-
ceiving Pem and 10.3 months for nonsquamous patients
receiving placebo (HR 0.70, p 0.002), which represented
a 30% reduction in the risk of death over the duration of the
study for nonsquamous patients receiving maintenance Pem.22
Overall, Pem maintenance therapy was well tolerated.
Drug-related grade 3/4 toxicities were higher for Pem com-
pared with placebo, particularly fatigue (5% versus 1%) and
neutropenia (3% versus 0%). Overall rates of transfusions
and growth factor use were generally low. Fewer patients in
the Pem arm compared with placebo (51% versus 67%; p 
0.0001) received systemic postdiscontinuation therapy.22 Re-
TABLE 1. Summary of Efficacy of Pemetrexed as Maintenance Therapy in Patients with
Advanced NSCLC22
Progression-Free Survival Overall Survival
Median
(mo)
Unadjusted
HR (95% CI) p
Median
(mo)
Unadjusted
HR (95% CI) p
All patients
(ITT population)
(N  663)
Pemetrexed 4.3 0.50 (0.42–0.61) 0.0001 13.4 0.79 (0.65–0.95) 0.012
Placebo 2.6 10.6
Nonsquamous
(N  481)
Pemetrexed 4.4 0.47 (0.37–0.60) 0.0001 15.5 0.70 (0.56–0.88) 0.002
Placebo 1.8 10.3
Squamous
(N  182)
Pemetrexed 2.4 1.03 (0.71–1.49) 0.896 9.9 1.07 (0.77–1.50) 0.678
Placebo 2.5 10.8
NSCLC, non-small cell lung cancer; CI  confidence interval; HR  hazard ratio; ITT  intent-to-treat.
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sults for the nonsquamous patients were similar to those for
all NSCLC patients.
Even though maintenance therapy is being used more
frequently in clinical practice, the economic value of main-
tenance therapy has not been evaluated in the medical liter-
ature. Grusenmeyer and Gralla24 evaluated the cost-effective-
ness of Bev/Carb/Pac as first-line therapy in patients with
advanced NSCLC. In the analysis, Bev was continued for
maintenance therapy; however, the cost-effectiveness of Bev
as maintenance therapy was not separated from the first-line
treatment. Thus, it is unclear whether maintenance therapy
with any of the aforementioned agents is cost-effective.
The objective of this study was to conduct a cost-
effectiveness analysis comparing the costs and benefits of
maintenance therapy with Pem plus BSC versus observation
plus BSC in patients with locally advanced or metastatic
(stage IIIB/IV) nonsquamous NSCLC after first-line therapy.
A secondary objective was evaluating the cost-effectiveness
of Pem maintenance therapy compared with maintenance
therapy with Erl or Bev in patients with advanced nonsqua-
mous NSCLC.
This study adds to the existing medical literature be-
cause it is the first time the cost-effectiveness of a mainte-
nance regimen in advanced NSCLC has been assessed. In
addition, histology has been used in this analysis to help
identify the most appropriate patient populations in which
maintenance therapy will provide the most clinical benefit
and be the most cost-effective.
PATIENTS AND METHODS
Model Structure
A semi-Markov state transition model was developed to
compare the short-term impact of maintenance therapy with
Pem plus BSC versus observation plus BSC or maintenance
therapy with Erl or Bev from a US payer perspective (i.e.,
only direct healthcare costs included). Details of the base case
are summarized (Table 2). Because of the increasing impor-
tance of histology in identifying the most appropriate candi-
dates for specific first-line therapies, this cost-effectiveness
analysis incorporates histology by defining two different
patient populations: (1) the base case, which represents pa-
tients with advanced nonsquamous NSCLC, and (2) all pa-
tients with advanced NSCLC (either squamous or nonsqua-
mous histology).
The model used estimates of NSCLC-related cost and
clinical outcomes attributable to the use of Pem in the 3 years
after completion of first-line chemotherapy. In terms of costs
and life-years (and thus cost-effectiveness ratios betweens
regimens), the 3-year timeframe is most representative be-
cause most patients have died and there is little difference
between regimens in terms of remaining costs and life-years
not yet accumulated.
Primary model outputs include discounted expected
costs and discounted life-years gained (LYG) over 3 years by
a patient initiating maintenance therapy after completion of
four cycles of a platinum-based induction regimen for ad-
vanced NSCLC. Incremental cost-effectiveness ratios (ICERs)
comparing maintenance therapy with Pem with observation, Erl,
or Bev were calculated.
Patients entering the model are assumed to have com-
pleted 4- and 3-week cycles of platinum doublet chemother-
apy for advanced NSCLC. Patients can begin one of the three
regimens of maintenance therapy or observation with BSC.
The prescribed regimens evaluated are Pem (500 mg/m2 of
body surface area [BSA] on day 1 of a 21-day cycle), Erl (150
mg/d), or Bev (15 mg/kg every 3 weeks). An unlimited
number of cycles of maintenance therapy per treatment arm
are assumed in the base case, with continuation allowed until
disease progression. Each therapy cycle (SD or the first
progressive disease [PD] cycle) can occur with mild or
serious side effects. Every 3 weeks, the model cohort is
redistributed among the following health states: PD, SD,
second-line treatment, SD without chemotherapy, PD without
chemotherapy, end-of-life care, and death (Figure 1).
Clinical Inputs
The clinical outcome of disease progression was in-
cluded in the model. Data for Pem and observation were
obtained from the prespecified subset of patients with
nonsquamous histology and the intent-to-treat (ITT) popula-
tion from the previously discussed trial.22 Transition rates, or
the probability of moving from one disease state to another,
were calculated by fitting to target progression, persistence,
TABLE 2. General Description of the Base Case Model
Parameter Base Case
Study therapies
and
maintenance
dose
Pem: 500 mg/m2 on day 1 of a 21-d cycle  BSCa
Observationa: BSC
Bev: 15 mg/kg day 1 of a 21-d cycle (BSC)b
Erl: 150-mg oral tablet per day for a 21-d cycle
(BSC)b
The model assumes an unlimited number of treatment
cycles for each maintenance therapy.
Patient
population
Patients with stage IIIB/IV NSCLC with
nonsquamous histology (i.e., adenocarcinoma, large
cell carcinoma, or not otherwise specified). Patients
completed four prior cycles of first-line platinum
chemotherapy with complete response, partial
response, or stable disease.
BSA 1.8 m2 for all applicable regimens
Mean patient
weight
70 kg for all applicable regimens
Model
perspective
US payer
Time horizon 3 yr
Benefits Life-years gained
Costs NSCLC-related direct health care costs including
chemotherapy, administration of chemotherapy,
laboratory monitoring, treating common adverse
events, subsequent therapies, direct care for
disease-related morbidity, and end-of-life care
Discount rate 3% for both benefits and costs
a Placebo was administered in the clinical trials of pemetrexed and erlotinib.
b Study descriptions do not explicitly state BSC but assumed to have been provided
to patients.
Bev, bevacizumab; BSA, body surface area; BSC, best supportive care; Erl,
erlotinib; Pem, pemetrexed; NSCLC, non-small cell lung cancer; US, United States.
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FIGURE 1. Tree diagram of health states. Every 3 weeks, the model cohort is redistributed among the following health
states: progressive disease, stable disease, second-line treatment, stable disease without chemotherapy, progressive disease
without chemotherapy, end-of-life care, and death. Bev, bevacizumab; chemo, chemotherapy; Erl, erlotinib; Pem,
pemetrexed.
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and death proportions obtained for Pem and observation from
survival curves.
No head-to-head data comparing the efficacy of main-
tenance therapy with Pem, Erl, or Bev are currently available.
Thus, efficacy data for Erl and Bev maintenance therapy came
from two different clinical trials. Clinical outcomes for Bev were
estimated from the control arm of a global, randomized, double-
blind, phase 3 clinical trial of Bev plus Erl versus Bev plus
placebo in patients with nonsquamous NSCLC.25 Clinical out-
comes for Erl were obtained from a randomized, controlled,
phase 3 clinical trial comparing Erl versus placebo.17,19 Each of
the phase 3 clinical trials that provided data for model inputs was
conducted in patients with stage IIIB/IV NSCLC who had
completed four cycles of platinum-based first-line chemotherapy
without disease progression before being randomized to main-
tenance therapy. For both Erl and Bev, the HR for PFS of the
comparator versus placebo was assumed to be comparable with
the HR of Pem compared with placebo from the JMEN trial.22
Relative hazards were used to estimate proportions progressed
over time and then transition probabilities were modified to fit
these proportions.
There were two types of side effects considered by the
model: mild side effects, which were indirectly reflected in
the model in the form of a treatment-specific expected cost of
mild side effects; and treatment-related serious adverse
events (SAEs), the probabilities of which are explicitly in-
cluded as model inputs specific to each treatment regimen.
Cycle-specific probabilities of maintenance treatment-related
SAEs with Pem were obtained from the Pem maintenance
trial (Table 3). Cycle-specific probabilities were not available
for the Erl or Bev maintenance regimens. In addition, the
types of toxicities related to Bev and Erl are different from
the toxicities associated with Pem. However, the adverse
event rates associated with Bev and Erl for toxicities that
could be considered serious were judged by the authors to be
neither better nor worse than Pem. Therefore, for the base
case, the authors assumed that the cycle-specific probabilities
of SAEs for Erl and Bev were equivalent to Pem. Based on
analysis of Bev maintenance therapy in the database de-
scribed below, this is conservative, because either the SAE
costs or SAE rates must be increased by about 50% to match
the costs attributable to SAEs during Bev maintenance.
Cost Inputs
NSCLC-related direct health care costs were incorpo-
rated into the model including the costs of chemotherapy
administration, laboratory monitoring, common side effects,
subsequent therapies, direct care for disease-related morbid-
ity, and end-of-life care (Table 4).
Drug costs for the maintenance chemotherapy regimens
were based on maximum allowable Medicare reimbursement
rates and average doses.26 Other direct NSCLC-related costs
were obtained from an analysis of the PharMetrics paid claims
database (PharMetrics Patient-Centric Database, PharMetrics,
Inc., a unit of IMS, Watertown, MA), which included data for
87,578 patients with possible lung cancer from January 2002
through January 2009. More than 37 million service lines from
institutional, professional, and pharmacy claims representing
nearly 100 health plans in the United States were analyzed. A
feature of the PharMetrics data is the grouping of each patient’s
claims into episodes of illness and coding of that illness with an
episode treatment group (ETG™) code.* To estimate other
direct NSCLC-related costs, ETG 0401, representing malignant
neoplasm of the pulmonary system without surgery, was com-
bined with ICD-9 diagnostic codes 162, 162.2, 162.3, 162.4,
162.5, 162.8, and 162.9, representing malignant neoplasm of the
bronchus or lung. Because ETG 0401 includes only individuals
who did not receive surgery, this helped to ensure that any
chemotherapy received was not adjuvant to a surgical therapy.
The costs of maintenance therapy were calculated as
part of a wider cost analysis investigating first-line, mainte-
nance, and subsequent treatment of NSCLC. Analysis was
restricted to patients receiving a first-line doublet of a plati-
num plus a taxane, Gem or Pem, or a first-line triplet of a
platinum, a taxane, and Bev. The sole maintenance regimen
investigated was Bev. Post hoc queries to identify possible
maintenance treatment with Erl found very few cases that
might be considered maintenance treatment.
Patients were excluded from the claims analysis if (1) a
diagnosis of lung cancer was made before 3 months before
first chemotherapy, (2) a diagnosis of other cancers was made
between 3 months and 2 years before first chemotherapy, (3)
the first chemotherapy occurred within the first month of
health plan eligibility, or (4) a sequence of 30 or more closely
spaced radiation treatments were received.
For each patient, the strategy of the analysis was to
identify the beginning and ending dates of each chemotherapy
regimen, identify beginning and ending dates of sequences of
chemotherapy treatment within each regimen, identify se-
quences of radiation treatment, accumulate the NSCLC treat-
ment costs incurred during the regimen, and calculate the length
of chemotherapy treatment. In addition, costs and durations were
accumulated for periods between chemotherapy treatments and,
for those patients identified as suffering death, accumulating
nontreatment costs incurred in the final 6 weeks of life.
Costs incurred could be attributed to more than 2800
different procedure and drug codes. These codes were
grouped into 59 procedure categories and drug groups. A
clinical consultant distributed costs to seven model inputs
based on code group and whether the cost was incurred
during or outside a period of chemotherapy: (1) chemother-
apy drugs, (2) chemotherapy administration and monitoring,
(3) managing mild side effects, (4) managing serious side
effects, (5) ongoing treatment of stable NSCLC, (6) ongoing
*“Episode Treatment Groups, ETGs, and ETG” are owned by Ingenix, Inc.,
and are used under a grant of license.
TABLE 3. Cycle-Specific Probabilities of Maintenance
Treatment-Related Serious Adverse Events
Cycle
1–4 5–7 8–11 12
Probability of serious adverse events 0.46% 2.08% 0.87% 0.15%
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treatment of progressive NSCLC, and (7) end-of-life care.
Three-week costs were calculated using the distributed costs,
durations of chemotherapy treatment, and durations between
and postchemotherapy treatment. Costs from the database
analysis were inflated to July 2009 US dollars using an
average annual medical inflation rate of 3.13%.
Because none of the maintenance therapy in the database
was Pem or Erl, some maintenance costs were estimated from
first-line costs, such as the cost of managing mild side effects of
Pem. The input costs for 3 weeks of treatment of SD and PD as
well as second-line chemotherapy were assumed not to depend
on maintenance and were calculated directly as weighted
averages of the 3-week values from the first-line analysis.
Likewise, the cost of an SAE was calculated as the weighted
average of first-line SAE costs. Finally, 3-week end-of-life
costs were calculated as half the weighted average of the final
6 weeks of costs for patients who died. Model inputs based on
the PharMetrics database appear within Table 4.
The model takes the perspective of a US health care
payer; thus, no nonmedical costs, such as patient transporta-
tion, or indirect costs, such as lost work, were considered.
Simple discounting of costs and benefits were performed at
3% per year, beginning with the second year.
Model Assumptions
Assumptions are inherent in any economic model due
to the model structure, limitations in available data, and the
need to simplify the model to deliver results that are under-
standable and reflect actual clinical practice. In this model, it
was assumed that probabilities change based on cycle and
current health state, but not previous health states as only
proportions of the cohort, and not individual patients, are mod-
eled. It was also assumed that all patients start the model in the
SD state; there is no differentiation based on the patients’ level
of response to first-line therapy. Transitions to death can occur
after any initial treatment cycle and from any health state and are
recorded at the midpoints of cycles. It was also assumed that
costs for the health states without chemotherapy are equivalent
regardless of the initial treatment. Once a patient discontinues
maintenance therapy, it was assumed that maintenance therapy
is not resumed and the model did not allow patients to switch to
an alternative maintenance therapy. No dose reductions or de-
lays between chemotherapy cycles were modeled. Each cycle of
second-line therapy was assumed to be associated with a 6%
probability of an SAE; the cost estimates reflect this assump-
tion. The same pattern of progression used for Pem was also
used for Erl and Bev, and all HRs were changed proportion-
ally to obtain the reported means and/or medians. Because
this resulted in a substantially longer median survival for Erl
than reported in the key phase 3 clinical trial evaluating
maintenance with Erl,17,19 the effectiveness of second-line
treatment after Erl maintenance was adjusted until the model
matched both PFS and OS from the clinical trial. The relative
effectiveness of Erl to observation was assumed to be inde-
pendent of histology.
TABLE 4. Cost Inputsa per 21-d Cycle of Maintenance Therapy
Parameter Pem Observation Erl Bev
Treatment costs
Dose 500 mg/m2 0 150 mg 15 mg/kg
Treatments per cycle 1 1 21 1
Vial or tablet size (mg) 500 0 150 100
Cost per vial or tablet ($) 2408.00 0 112.51 574.04
Total drug cost per cycle ($) 4776.80b 0 2363.00 6314.44
Disease and adverse event monitoring costs ($) 485.00 0 485.00 791.00
Administration costs ($) 161.00 0 0 161.00
Total treatment, administration, and monitoring costs ($) 5422.80 0 2848.00 7266.44
Adverse event costs
Expected costs of mild or no side effects ($) 55.00 0 55.00 80.00
Cost to treat an SAE (per episode) ($) 12,568.00 0 12,568.00 12,568.00
Second-line costs
Second-line treatment costs (per cycle) ($) 6128.00 6128.00 6128.00 6128.00
Second-line side effect costs (mean, per cycle) ($) 754.08 754.08 754.08 754.08
Total second-line treatment and side effect costs ($) 6882.08 6882.08 6882.08 6882.08
Other costs
End-of-life care costs (per cycle) ($) 5306.00 5306.00 5306.00 5306.00
Stable disease treatment costs without chemotherapy (per cycle) ($) 343.00 343.00 343.00 343.00
Ongoing costs for treatment of progressive disease (per cycle) ($) 1894.00 1894.00 1894.00 1894.00
a Drug costs for the maintenance chemotherapy regimens are based on maximum allowable Medicare reimbursement rates and average doses
(CMS 2009). All other direct NSCLC-related costs were obtained from an analysis of the PharMetrics Patient-Centric Database (PharMetrics, Inc.,
a unit of IMS, Watertown, MA).
b To avoid wastage resulting from the use of only 500-mg vials, the model assumes 8.2% of patients will receive Pem therapy via a 100-mg vial
to round off their dose at a cost of $482 per vial. This base case utilization rate of 8.2% is based on market research data spanning January 2008 (when
the 100-mg vial was introduced to the US market) through February 2009.
Bev, bevacizumab; Erl, erlotinib; NSCLC, non-small cell lung cancer; Pem, pemetrexed; SAE, serious adverse event; CMS, Centers for Medicare
and Medicaid Services.
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Because the progression and survival data are based on
a clinical trial that included only patients with performance
status (PS) of 0 or 1 (asymptomatic or symptomatic but
completely ambulant), inferences from the model results
should be limited to that subpopulation. In addition, Pem
dosing assumes that all patients have a BSA of 1.8 m2, and
Bev dosing assumes that all patients weigh 70 kg.
Sensitivity Analyses
One-way and probabilistic sensitivity analyses were
conducted to evaluate the importance of uncertainty in the
modeled input values and the overall variability of the cost-
effectiveness of Pem maintenance therapy. The maximum
number of maintenance cycles received was varied from
unlimited in the base case to 4, 8, and 17 cycles. The discount
rate was varied from 3% to undiscounted and 5%. The
probabilities of receiving second-line therapy after progres-
sion during maintenance therapy were varied independently
from 50% for Pem and 60% for observation to 40% and 60%
for Pem and 50% and 70% for observation. The timeframe of
the model was doubled from 3 years to reflect 6-year costs. In
addition, the frequency of using the 100-mg vial size of Pem
was increased to 25%.
RESULTS
Base case results compared maintenance therapy with
Pem plus BSC compared with observation plus BSC in
patients with nonsquamous NSCLC for the time period of 3
years after completion of first-line chemotherapy (Table 5).
Pem maintenance therapy added approximately 13.6 (14.0
undiscounted) weeks of life (0.261 LYG) compared with
observation at an additional discounted cost of $31,944. The
ICER for Pem to observation measuring the incremental cost
divided by the incremental LYG was $122,371.
Maintenance therapy with Pem was compared with
maintenance therapy with Erl. Pem maintenance therapy
added approximately 8.5 weeks of life (0.163 LYG) com-
pared with Erl maintenance therapy at an additional cost of
$24,474. The ICER for Pem to Erl was $150,260.
Maintenance therapy with Pem was also compared with
maintenance therapy with Bev. Pem added approximately 2.5
weeks of life (0.048 LYG) compared with Bev but costs
$9,187 less. Therefore, maintenance therapy with Bev was
dominated by Pem.
In the second population of patients with advanced
NSCLC including patients with either squamous or nonsqua-
mous histology, maintenance therapy with Pem plus BSC added
approximately 7.1 weeks of life (0.137 LYG) compared with
observation plus BSC at an additional cost of $28,253 (Table 5).
The ICER for Pem to observation was $205,597.
Maintenance therapy with Pem was also compared with
maintenance therapy with Erl in all patients with advanced
NSCLC including those with either squamous or nonsqua-
mous cell histology. Pem maintenance therapy added approx-
imately 3.0 weeks of life (0.058 LYG) compared with Erl
maintenance therapy at an additional cost of $18,142. The
ICER for Pem to Erl was $312,341.
Sensitivity Analyses Results
Limiting the number of maintenance cycles received
was the only sensitivity analysis that produced a substantial
change in the ICER (Figure 2). Limiting the number of cycles
to four decreased costs of Pem by $17,172 and reduced the
ICER to $86,610 per LYG. This analysis assumes that the
transition rates after discontinuation (death and progression)
are the same as in the phase 3 clinical trial evaluating
maintenance therapy with Pem, independent of the duration
of treatment. None of the transition rates after treatment ends
depended on how long maintenance treatment lasted. Thus,
the cost-effectiveness argument for Pem maintenance therapy
versus observation would be much stronger if the number of
cycles was limited. However, physicians may be reluctant to
discontinue treatment that is well tolerated and effective. The
impact of varying discount rates, the frequency of using the
100-mg vial size for Pem, the probability of receiving sec-
ond-line therapy after maintenance therapy, and the model
timeframe had little impact on the ICERs.
Probabilistic sensitivity analyses were conducted by
replacing key input parameter point estimates with distribu-
tions representing a range of uncertainty. The willingness to
pay curve shows that nearly 90% of estimated ICERs using
samples varying costs and SAE event rates were between
$100,000 and $150,000 per LYG, with the 50th percentile
very close to the base case (Figure 3).
DISCUSSION
This study provides information on the cost-effective-
ness of maintenance therapy with Pem plus BSC compared
with observation plus BSC, Erl, or Bev after first-line che-
motherapy in patients whose disease has not progressed. The
TABLE 5. Cost-Effectiveness of Maintenance
Chemotherapy in Patients with Stage IIIB/IV Nonsquamous
NSCLC for 3 yr
Cost-Effectiveness Analysis Cost ($) Life-Years ICER ($)
Nonsquamous cell NSCLC
onlya
Observation 64,830 1.0802
Erl 72,300 1.1784
Pem 96,774 1.3412
Bev 105,961 1.2933
Incremental Pem to
observation
31,944 0.2610 122,371
Incremental Pem to Erl 24,474 0.1629 150,260
Incremental Bev to Pem 9187 0.0480 Dominated
Squamous and nonsquamous
cell NSCLC
Observation 61,036 1.1060
Erl 71,147 1.1854
Pem 89,289 1.2434
Incremental Pem to
observation
28,253 0.1374 205,597
Incremental Pem to Erl 18,142 0.0581 312,341
a Includes patients with adenocarcinoma, large cell carcinoma, and other or not
otherwise specified histology.
Bev, bevacizumab; Erl, erlotinib; ICER, incremental cost-effectiveness ratio;
NSCLC, non-small cell lung cancer; Pem, pemetrexed.
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main focus of this study was to evaluate the cost-effective-
ness of Pem with BSC compared with observation with BSC
based on clinical trial data in a patient population with
advanced nonsquamous NSCLC. Other comparisons between
maintenance therapy with Pem versus Erl or Bev can be
considered secondary and preliminary because crude indirect
comparisons of efficacy were used.
This analysis emphasizes the importance of histology in
targeting the appropriate patient for Pem maintenance ther-
apy. In an advanced NSCLC population with both squamous
and nonsquamous cell histology, Pem maintenance therapy is
unlikely to be considered cost-effective. However, the ICERs
for Pem compared with observation were much lower (more
cost-effective) in patients with nonsquamous cell histology.
An analysis by Grusenmeyer and Gralla24 evaluated the
cost-effectiveness of adding Bev to Carb/Pac as first-line
therapy in patients with advanced NSCLC. After first-line use
of the triplet, Bev was continued as maintenance therapy until
disease progression. Although the triplet added approxi-
mately 2.3 months to median survival, it did so at an incre-
mental cost of $66,270. Adding Bev to Carb/Pac yielded a
cost of more than $340,000 per LYG and was not considered
cost-effective by the authors. This cost-effectiveness analysis
focused on the use of Bev as part of a triplet regimen
followed by single-agent maintenance therapy. It did not
isolate the contribution of maintenance Bev therapy to the
incremental benefits and costs. Thus, the cost-effectiveness of
Bev maintenance therapy cannot be inferred from the study.
Carlson et al.27 evaluated the cost-effectiveness of Erl as second-
line therapy in the treatment of refractory stage IIB/IV NSCLC.
However, the results focused on the use of Erl as second-line
therapy and cannot be used to infer cost-effectiveness as main-
tenance therapy.
The base case cost per LYG for maintenance therapy
with Pem plus BSC compared with observation plus BSC
may not be considered cost-effective when compared with a
commonly mentioned threshold of $100,000 per LYG in the
United States. However, this threshold is often criticized for
being outdated and not taking into consideration the severity
of the condition. In addition, this threshold is not well
documented in the medical literature. Braithwaite et al.28
have recently developed plausible lower and upper bounds
for cost-effectiveness decision rules in the United States
ranging from $95,000 per LYG to $264,000 per LYG. Based
on these revised thresholds, in a population with advanced,
nonsquamous NSCLC, maintenance therapy with Pem is
cost-effective compared with observation or Erl.
The current study is the first to demonstrate that main-
tenance therapy with Pem in advanced NSCLC is cost-
effective in patients with nonsquamous cell histology. How-
FIGURE 2. Effect of select assumptions and uncertainty in model inputs in predicting the cost-effectiveness of maintenance
therapy with Pem compared with observation in patients with advanced NSCLC. This tornado diagram shows that most rea-
sonable changes in input parameters had little impact on the ICER for maintenance Pem to observation. Base case ICER for
maintenance Pem versus observation was $122,371 per LYG. When a range of input values was modeled, the red portion of
the bar corresponds to the effect of the lower input value and the blue portion of the bar corresponds to the higher value.
ICER, incremental cost-effectiveness ratio; LYG, life-year gained; NSCLC, non-small cell lung cancer; Pem, pemetrexed.
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ever, as with any cost-effectiveness analysis, there are
limitations that may require additional research. Because the
response and survival data are based on a phase 3 clinical trial
that included only patients with stage IIIB or IV NSCLC with
performance status 0 or 1 who had completed four cycles of
one of the six induction regimens and who did not have PD,
inferences from the model results should be limited to this
subpopulation.
The model estimated that Pem maintenance therapy led
to an additional 0.261 life-years (13.6 weeks of life) when
compared with observation. This difference was substantially
less than the 22.6 weeks reported for the nonsquamous
population in the phase 3 clinical trial of maintenance Pem
versus placebo.22 Although there is no difference in PFS
between the model and the clinical trial, after the end of the
first year, people off treatment were given no residual benefit
in the model, so subsequent survival curves were similar.
This conservative assumption produced a lower LYG for Pem
maintenance therapy. In addition, all modeled results were
discounted at 3% per year.
At the time of the analysis, Erl and Bev were not
indicated as maintenance therapy in patients with advanced
NSCLC, and there are no head-to-head data comparing the
efficacy of maintenance therapy with Pem to maintenance
therapy with either agent. As such, this model relies on crude
indirect comparisons of each agent against placebo. Clinical
data for Erl maintenance therapy are based on data from a
phase 3 clinical trial versus placebo. Bev efficacy data are
based on a clinical trial that compares Bev to Bev plus Erl. It
was assumed that populations were comparable with that in
the JMEN trial, which compared maintenance therapy with
Pem to placebo.
Direct NSCLC-related costs included in the model are
from a claims database analysis whose data date back to
2002. Although these analyses can represent real world costs
and utilization, there are limitations associated with database
analyses including potential diagnostic or procedural coding
inaccuracies, incomplete data, and lack of generalizability of
findings to other types of third-party payers (e.g., Medicare
and Medicaid). In addition, because the database represented
medical claims, it did not contain useful clinical data such as
histology, stage, performance status, or health status, which
may affect treatment costs. Pem and Erl were not indicated
for maintenance therapy during the years covered in the
database analysis, and there was slightly more than 1 year’s
worth of data for Bev maintenance therapy. Of the approxi-
mately 300 patients who received a first-line triplet of a
platinum, a taxane, and Bev, 70 of these patients received
Bev maintenance therapy for a total of 1106 weeks. Thus,
there were very few cases of patients treated with these agents
as maintenance therapy within the database cost analysis.
The results of this study may not be generalizable to all
health care systems or payers. This analysis is based on a US
payer perspective and is limited to direct lung cancer-related
medical costs. No accounting for direct nonmedical costs,
FIGURE 3. Willingness-to-pay for pemetrexed maintenance therapy compared with observation. Approximately 90% of
ICERs estimated using samples varying costs and SAE event rates were between $100,000 and $150,000 per LYG. ICER, incre-
mental cost-effectiveness ratio; LYG, life-year gained; SAE, serious adverse event.
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such as transportation, or indirect societal costs, such as lost
productivity or caregiver costs, are included.
In conclusion, this study is the first to demonstrate the
cost-effectiveness of maintenance therapy with Pem in pa-
tients with advanced nonsquamous NSCLC. The cost-effec-
tiveness of maintenance therapy with Pem is driven by its
significant improvement in PFS and OS in patients with
advanced nonsquamous NSCLC. This study emphasizes the
importance of histology in assessing the incremental benefits
and costs of Pem as maintenance therapy. In an unselected,
advanced, NSCLC population with either squamous or nonsqua-
mous cell histology, Pem maintenance therapy is unlikely to be
considered cost-effective; however, in the FDA-approved pop-
ulation of patients with nonsquamous cell NSCLC, the ICER
of Pem to observation shows that this may be a cost-effective
treatment option.
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